Zobrazeno 1 - 10
of 389
pro vyhledávání: '"Jeffrey M Switchenko"'
Autor:
Peng Li, Haydn Kissick, Rebecca C Obeng, Tahseen H Nasti, Christiane S Eberhardt, Rafi Ahmed, Zhengjia Chen, Warren J Leonard, Suresh S Ramalingam, Andreas Wieland, Annapaola Mariniello, Jeffrey M Switchenko, Kylee Martens, Daniel Y Chang, Donald McGuire, Candace Daugherty, Yuzi Zhang, Rathi Pillai, Alice O Kamphorst
Publikováno v:
BMJ Oncology, Vol 3, Iss 1 (2024)
Objective Immune checkpoint inhibitors (ICI) that block the programmed cell death 1 (PD-1) pathway have shown promise with limited benefit. We and others have shown in small patient cohorts that an early proliferative CD8 T-cell response in the blood
Externí odkaz:
https://doaj.org/article/4cc0e384a52945fa895729f71406f6ed
Autor:
Gregory B Lesinski, Christina Wu, Mehmet Akce, Brian Olson, Maria Diab, Batoul Farran, Jeffrey M Switchenko, Manali Rupji, Sandra Kang, Lana Khalil, Amanda Ruggieri-Joyce, Walid L Shaib, Olatunji B Alese, Bassel F El-Rayes
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)
Background Preclinical studies showed metformin reduces exhaustion of tumor-infiltrating lymphocytes and potentiates programmed cell death protein-1 (PD-1) blockade. We hypothesized that metformin with nivolumab would elicit potent antitumor and immu
Externí odkaz:
https://doaj.org/article/2bc4352546204629923aab3d10545a4e
Publikováno v:
PLoS ONE, Vol 14, Iss 9, p e0221336 (2019)
BackgroundRandomized clinical trials compare participants receiving an experimental intervention to participants receiving standard of care (SOC). If one could predict the outcome for participants receiving SOC, a trial could be designed where all pa
Externí odkaz:
https://doaj.org/article/1b63c32eb0474b8cb902c5a55a7d1333
Autor:
Shannon M. Blee, Jamil Facdol, Margie D. Dixon, Viraj Master, Jeffrey M. Switchenko, Rebecca D. Pentz
Publikováno v:
Cancer Medicine, Vol 11, Iss 7, Pp 1678-1687 (2022)
Abstract Background Previously, we showed that chemotherapy terminology is difficult for patients to understand. Therefore, we developed short videos explaining key terminology and though proven effective, they will only be helpful if appropriately d
Externí odkaz:
https://doaj.org/article/d79ddd56f52b4d2a9074e300b7fa1834
Autor:
Sagar A. Patel, Jeffrey M. Switchenko, Ben Fischer-Valuck, Chao Zhang, Brent S. Rose, Ronald C. Chen, Ashesh B. Jani, Trevor J. Royce
Publikováno v:
Radiation Oncology, Vol 15, Iss 1, Pp 1-7 (2020)
Abstract Background Ultrahypofractionation using stereotactic body radiotherapy (SBRT) is an increasingly utilized technique for men with prostate cancer (PC). The comparative efficacy of SBRT plus androgen deprivation therapy (ADT) compared to fract
Externí odkaz:
https://doaj.org/article/23b99fde720845aca8d0730f3178701a
Autor:
Narendranath, Epperla, Jeffrey M, Switchenko, Veronika, Bachanova, James N, Gerson, Stefan K, Barta, Max J, Gordon, Alexey V, Danilov, Natalie Sophia, Grover, Stephanie P, Mathews, Madelyn, Burkart, Reem, Karmali, Yazeed, Sawalha, Brian T, Hill, Nilanjan, Ghosh, Steven I, Park, David A, Bond, Mehdi, Hamadani, Timothy S, Fenske, Peter, Martin, Jin, Guo, Mary-Kate, Malecek, Brad S, Kahl, Christopher R, Flowers, Brian K, Link, Lawrence D, Kaplan, David J, Inwards, Andrew, Feldman, Eric D, Hsi, Kami, Maddocks, Kristie, Blum, Namcy L, Bartlett, James R, Cerhan, John P, Leonard, Thomas M, Habermann, Matthew J, Maurer, Jonathon B, Cohen
Publikováno v:
Blood Advances. 7:2287-2296
The prognostic relevance of diagnosis to treatment interval (DTI) in patients with newly diagnosed mantle cell lymphoma (MCL) is unknown. Hence, we sought to evaluate the impact of DTI on outcomes in MCL using 3 large datasets (1) the University of I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::423376d1bb6375957228504a7eecacbc
https://doi.org/10.1182/bloodadvances.2022009225
https://doi.org/10.1182/bloodadvances.2022009225
Autor:
Peter Martin, Jonathon B. Cohen, Michael Wang, Anita Kumar, Brian Hill, Diego Villa, Jeffrey M. Switchenko, Brad Kahl, Kami Maddocks, Natalie S. Grover, Keqin Qi, Lori Parisi, Katherine Daly, Angeline Zhu, Gilles Salles
Publikováno v:
Journal of Clinical Oncology. 41:541-554
PURPOSE Commonly used first-line (1L) treatments for mantle cell lymphoma include high-dose cytarabine-based induction followed by autologous stem-cell transplant (ASCT) for younger patients and several chemoimmunotherapy regimens for older patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83653f7785aae329b38d8e8a182ebf0e
https://doi.org/10.1200/jco.21.02698
https://doi.org/10.1200/jco.21.02698
Autor:
James R. Janopaul‐Naylor, Manali Rupji, Rachel A. Tobillo, Joshua W. Lorenz, Jeffrey M. Switchenko, Sibo Tian, Azeem S. Kaka, David C. Qian, Ashley J. Schlafstein, Conor E. Steuer, Jill S. Remick, Soumon Rudra, Mark W. McDonald, Nabil F. Saba, William A. Stokes, Mihir R. Patel, James E. Bates
Publikováno v:
Head & Neck. 45:658-663
Postoperative mortality for oropharynx squamous cell carcinoma (OPSCC) with transoral robotic surgery (TORS) varies from 0.2% to 6.5% on trials; the real-world rate is unknown.NCDB study from 2010 to 2017 for patients with cT1-2N0-2M0 OPSCC with Char
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da33aeb2a92951ab660085c3b4248d0f
https://doi.org/10.1002/hed.27282
https://doi.org/10.1002/hed.27282
Autor:
Andres Chang, Akil Akhtar, Lilin Lai, Victor M. Orellana-Noia, Susanne L. Linderman, Ashley A. McCook-Veal, Jeffrey M. Switchenko, Manpreet Saini, Rajesh M. Valanparambil, Kristie A. Blum, Pamela B. Allen, Mary Jo Lechowicz, Jason T. Romancik, Amy Ayers, Alyssa Leal, Colin B. O'Leary, Michael C. Churnetski, Katelin Baird, Melissa Kives, Jens Wrammert, Ajay K. Nooka, Jean L. Koff, Madhav V. Dhodapkar, Mehul S. Suthar, Jonathon B. Cohen, Rafi Ahmed
Publikováno v:
Cancer Research Communications. 2:1684-1692
Patients with non–Hodgkin lymphoma and chronic lymphocytic leukemia (NHL/CLL) elicit inadequate antibody responses after initial SARS-CoV-2 vaccination and remain at high risk of severe COVID-19 disease. We investigated IgG, IgA, and IgM responses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2dba9bfe1a34844f16a5b22d8df72770
https://doi.org/10.1158/2767-9764.crc-22-0471
https://doi.org/10.1158/2767-9764.crc-22-0471
Autor:
Maryam I. Azeem, Ajay K. Nooka, Uma Shanmugasundaram, Narayanaiah Cheedarla, Sayalee Potdar, Renee Julia Manalo, Alberto Moreno, Jeffrey M. Switchenko, Suneethamma Cheedarla, Deon Bryant Doxie, Roman Radzievski, Madison Leigh Ellis, Kelly E. Manning, Bushra Wali, Rajesh M. Valanparambil, Kathryn T. Maples, Essence Baymon, Jonathan L. Kaufman, Craig C. Hofmeister, Nisha S. Joseph, Sagar Lonial, John D. Roback, Alessandro Sette, Rafi Ahmed, Mehul S. Suthar, Andrew S. Neish, Madhav V. Dhodapkar, Kavita M. Dhodapkar
Publikováno v:
Blood Cancer Discovery. 4:106-117
Patients with multiple myeloma (MM) mount suboptimal neutralizing antibodies (nAb) following 2 doses of SARS-CoV-2 mRNA vaccines. Currently, circulating SARS-CoV-2 variants of concern (VOC) carry the risk of breakthrough infections. We evaluated immu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c80245436565a67f2a8a7f212f7b3bc
https://doi.org/10.1158/2643-3230.bcd-22-0173
https://doi.org/10.1158/2643-3230.bcd-22-0173